Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Lopez ZKJ, Piketty C et al (2023) Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol 159(11):1205

Article  PubMed  PubMed Central  Google Scholar 

Yook HJ, Lee JH (2024) Prurigo nodularis: pathogenesis and the Horizon of potential therapeutics. Int J Mol Sci 25(10):5164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L et al (2023) Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol 23(14):1301817

Article  Google Scholar 

Girolomoni G, Maurelli M, Gisondi P (2022) The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Ital J Dermatol Venerol 157(4):306–312

PubMed  Google Scholar 

Ständer S, Augustin M, Berger T, Elmariah S, Korman NJ, Weisshaar E et al (2020) Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int 1(2):28

Google Scholar 

Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S et al (2018) Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 79(4):714

Article  PubMed  PubMed Central  Google Scholar 

Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA et al (2021) Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol 46(7):1277–1284

Article  CAS  PubMed  Google Scholar 

Olbrich H, Kridin K, Hernández G, Zirpel H, Sadik CD, Terheyden P et al (2024) Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study. eBioMedicine 103:105123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whang KA, Kang S, Kwatra SG (2019) Inpatient burden of prurigo nodularis in the United States. Medicines 6(3):88

Article  PubMed  PubMed Central  Google Scholar 

Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N et al (2022) Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol 86(3):573–580

Article  PubMed  Google Scholar 

Taghaddos D, Savinova I, Abu-Hilal M (2024) Clinical characteristics and treatment outcomes of prurigo nodularis: a retrospective study. J Cutan Med Surg 28(2):141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bewley A, Homey B, Pink A (2022) Prurigo nodularis: a review of IL-31RA blockade and other potential treatments. Dermatol Ther 12(9):2039

Article  Google Scholar 

Ständer S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A et al (2022) Nemolizumab effectiveness in prurigo nodularis: onset of action on itch and sleep disturbances. J Euro Acad Dermatol Venereol 36(10):1820–5

Article  Google Scholar 

Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xiang X, Patrick MT et al (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol 149(4):1329

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71

Article  Google Scholar 

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 18(343):d5928

Article  Google Scholar 

Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al (2023) Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 389(17):1579–1589

Article  CAS  PubMed  Google Scholar 

Yokozeki H, Murota H, Matsumura T, Komazaki H, or the Nemolizumab-JP11 Study Group (2024) Effectiveness and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years. Br J Dermatol 191(2):200–8

Article  PubMed  Google Scholar 

Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J et al (2020) Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 382(8):706–716

Article  PubMed  Google Scholar 

Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18(2):e1230

Article  PubMed  PubMed Central  Google Scholar 

Dermatology Times [Internet]. 2024 [cited 2024 Oct 22]. FDA Approves Nemolizumab for the Treatment of Prurigo Nodularis. Available from: https://www.dermatologytimes.com/view/fda-approves-nemolizumab-for-the-treatment-of-prurigo-nodularis

Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N et al (2021) Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 84(3):747–760

Article  PubMed  Google Scholar 

Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT (2019) Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol 28(12):163

Article  Google Scholar 

Liao V, Cornman HL, Ma E, Kwatra SG (2024) Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol 190(6):798–810

Article  PubMed  PubMed Central  Google Scholar 

Dermatology Times [Internet]. 2024 [cited 2024 Oct 22]. Late-Breaking Data: Long-Term Safety and Effectiveness of Largest Prurigo Nodularis Study Ever Conducted. Available from: https://www.dermatologytimes.com/view/late-breaking-data-long-term-safety-and-effectiveness-of-largest-prurigo-nodularis-study-ever-conducted

Müller S, Zeidler C, Ständer S (2023) Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol 25(1):15

Article  PubMed  PubMed Central  Google Scholar 

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study - ScienceDirect [Internet]. [cited 2024 Oct 22]. Available from: https://www.sciencedirect.com/science/article/pii/S0091674918306985

Kabashima K, Matsumura T, Hayakawa Y, Kawashima M, Nemolizumab-JP01 Study Group (2023) Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial. J Dermatolog Treat 34(1):2177096

Article  PubMed  Google Scholar 

Nemolizumab shows long-term effectiveness in treatment of prurigo nodularis, atopic dermatitis [Internet]. [cited 2024 Oct 22]. Available from: https://www.healio.com/news/dermatology/20240314/nemolizumab-shows-longterm-effectiveness-in-treatment-of-prurigo-nodularis-atopic-dermatitis